Does GLP-1 help with cortisol levels? This question arises as GLP-1 receptor agonists gain prominence for type 2 diabetes and weight management. Cortisol, the body's primary stress hormone, plays a crucial role in metabolism and stress response. Whilst GLP-1 medications such as semaglutide and liraglutide are licensed in the UK for specific metabolic indications, they are not approved for treating cortisol disorders. This article examines the current evidence regarding any potential relationship between GLP-1 therapy and cortisol regulation, clarifying what these medications can and cannot achieve within UK clinical practice.

What Are GLP-1 Medications and How Do They Work?

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications licensed in the UK for specific indications. For type 2 diabetes mellitus, options include semaglutide (Ozempic), dulaglutide (Trulicity), liraglutide (Victoza), and exenatide (Byetta, Bydureon). For weight management, semaglutide (Wegovy) and liraglutide (Saxenda) are available through specialist services under specific NICE criteria.

GLP-1 is a naturally occurring incretin hormone produced by intestinal L-cells in response to food intake. The synthetic GLP-1 receptor agonists mimic this endogenous hormone but are modified to resist rapid enzymatic breakdown by dipeptidyl peptidase-4 (DPP-4), thereby extending their duration of action. The primary mechanism of action involves binding to GLP-1 receptors on pancreatic beta cells, which stimulates glucose-dependent insulin secretion whilst simultaneously suppressing glucagon release from alpha cells. This dual action helps to regulate blood glucose levels without causing significant hypoglycaemia when used as monotherapy, though the risk increases when combined with insulin or sulfonylureas.

Beyond glycaemic control, GLP-1 receptor agonists exert several additional metabolic effects. They slow gastric emptying, which prolongs satiety and reduces postprandial glucose excursions. Centrally, these medications act on appetite-regulating centres in the hypothalamus, leading to reduced caloric intake and subsequent weight loss.

NICE guidance (NG28) recommends GLP-1 receptor agonists for adults with type 2 diabetes who have inadequate glycaemic control despite optimal management with metformin and other oral agents, particularly when significant weight loss would be beneficial. Treatment should be reassessed after 6 months and discontinued if not achieving adequate improvements in both HbA1c and weight.

Common adverse effects include nausea, vomiting, diarrhoea, and injection site reactions, which typically diminish with continued use. More serious potential side effects include pancreatitis, gallbladder disease, risk of acute kidney injury with severe gastrointestinal effects, and possible worsening of diabetic retinopathy with semaglutide. These medications are contraindicated in pregnancy and breastfeeding. Patients should report suspected side effects via the MHRA Yellow Card scheme.

Understanding Cortisol: The Body's Stress Hormone

Cortisol is a vital glucocorticoid hormone produced by the adrenal cortex in response to stimulation by adrenocorticotropic hormone (ACTH) from the pituitary gland. This hormone plays an essential role in numerous physiological processes, including glucose metabolism, immune function regulation, blood pressure maintenance, and the body's response to physical and psychological stress. Cortisol secretion follows a characteristic diurnal rhythm, with levels typically peaking in the early morning (around 8am) and reaching their nadir around midnight.

When functioning normally, cortisol helps mobilise energy stores during periods of stress by promoting gluconeogenesis (glucose production) in the liver, increasing protein breakdown, and facilitating lipolysis. It also possesses anti-inflammatory and immunosuppressive properties. However, dysregulation of cortisol production—whether excessive (hypercortisolism) or insufficient (hypocortisolism)—can lead to significant health consequences.

Chronic elevation of cortisol levels, as seen in Cushing's syndrome, is associated with multiple adverse effects including:

• Central obesity and metabolic syndrome

• Insulin resistance and type 2 diabetes

• Hypertension and cardiovascular disease

• Osteoporosis and increased fracture risk

• Mood disturbances, anxiety, and depression

• Impaired immune function and wound healing

Psychological stress can affect cortisol patterns, though the relationship is complex and varies between individuals. Some may experience elevated levels, while others show flattened diurnal variation or other altered patterns.

Conversely, cortisol deficiency (Addison's disease or secondary adrenal insufficiency) presents with fatigue, weight loss, hypotension, and potentially life-threatening adrenal crisis. The hypothalamic-pituitary-adrenal (HPA) axis tightly regulates cortisol production through negative feedback mechanisms, and disruption at any level can result in pathological cortisol states requiring medical intervention.

Managing Cortisol Levels: Treatment Options in the UK

Management of abnormal cortisol levels in the UK depends entirely on the underlying aetiology and whether the patient presents with hypercortisolism or hypocortisolism. For patients with Cushing's syndrome (cortisol excess), NICE recommends specialist endocrinology referral for comprehensive investigation and management. Initial assessment typically includes 24-hour urinary free cortisol measurement, late-night salivary cortisol testing, or low-dose dexamethasone suppression testing to confirm hypercortisolism.

Once diagnosed, treatment depends on the cause. Pituitary adenomas (Cushing's disease) are usually managed with trans-sphenoidal surgery as first-line treatment. When surgery is unsuccessful or contraindicated, medical therapies may be employed. Osilodrostat (Isturisa) is NICE-approved for Cushing's disease when surgery is unsuitable or has failed. Other options include pasireotide (which requires blood glucose monitoring due to hyperglycaemia risk), metyrapone, or ketoconazole (used off-label for Cushing's with liver function monitoring). Adrenal tumours typically require surgical adrenalectomy, whilst ectopic ACTH-secreting tumours necessitate identification and removal of the primary malignancy when feasible.

For stress-related cortisol patterns without pathological hypercortisolism, management focuses on lifestyle interventions and psychological support. Evidence-based approaches include:

• Cognitive behavioural therapy (CBT) and stress management techniques

• Regular physical activity and adequate sleep hygiene

• Mindfulness-based stress reduction programmes

• Addressing underlying anxiety or depression with appropriate psychological or pharmacological interventions

Patients with adrenal insufficiency require lifelong glucocorticoid replacement therapy, typically with hydrocortisone (15–25mg daily in divided doses) to mimic physiological cortisol secretion patterns. Those with primary adrenal insufficiency also need mineralocorticoid replacement with fludrocortisone. All patients should carry a Steroid Emergency Card and have an emergency hydrocortisone injection kit with education on its use. The NHS provides specialist endocrine input for dose optimisation and patient education regarding sick-day rules and emergency management.

Urgent medical attention is essential for suspected adrenal crisis, characterised by severe vomiting, diarrhoea, confusion, profound weakness, or hypotension.

Does GLP-1 Help with Cortisol Levels? Current Evidence

There is currently no official link established between GLP-1 receptor agonist therapy and direct therapeutic effects on cortisol levels in humans. These medications are not licensed or recommended by NICE, the MHRA, or the EMA for the treatment of hypercortisolism or stress-related cortisol dysregulation. The primary indications remain type 2 diabetes mellitus and obesity management in carefully selected patients.

However, emerging preclinical and limited clinical research has explored potential indirect relationships between GLP-1 signalling and the HPA axis. Animal studies have suggested that GLP-1 receptors are expressed in various brain regions, including areas involved in stress response regulation. Some experimental evidence indicates that GLP-1 receptor activation might modulate stress-induced behaviours and potentially influence HPA axis activity, though these findings have not been consistently replicated in human studies.

Small-scale human studies have produced mixed and inconsistent results. Some limited research has observed modest changes in cortisol patterns in patients treated with GLP-1 receptor agonists, but these effects appear to be secondary consequences of metabolic improvement rather than direct pharmacological actions on cortisol production. Many studies have found no significant changes in basal or stimulated cortisol levels with GLP-1 therapy.

It is important to emphasise that any observed cortisol changes in patients receiving GLP-1 medications are likely attributable to:

• Weight reduction and improved body composition

• Enhanced insulin sensitivity and glycaemic control

• Reduced systemic inflammation

• Potential improvements in sleep quality and psychological well-being

Patients concerned about cortisol levels should not consider GLP-1 medications as a treatment option without appropriate medical evaluation. If you suspect abnormal cortisol production, consult your GP for proper investigation, which may include referral to endocrinology services. GLP-1 receptor agonists should only be prescribed according to their licensed indications and NICE-approved criteria, following comprehensive assessment by a qualified healthcare professional.

Frequently Asked Questions